A Trial of Pembrolizumab in Combination With Doxorubicin as Treatment for Patients With Advanced Sarcomas
Latest Information Update: 08 Apr 2022
At a glance
- Drugs Doxorubicin (Primary) ; Pembrolizumab (Primary)
- Indications Sarcoma; Soft tissue sarcoma
- Focus Adverse reactions; Therapeutic Use
- 21 Oct 2020 Status changed from active, no longer recruiting to completed.
- 14 May 2020 Planned End Date changed from 1 Jun 2020 to 1 Jun 2021.
- 04 Jun 2019 Results presented at the 55th Annual Meeting of the American Society of Clinical Oncology